



Scan the QR code. The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

VISIBLE COHORT A: GUSELKUMAB SKIN CLEARANCE AND PATIENT-REPORTED OUTCOMES ACROSS SKIN AND JOINT SYMPTOMS THROUGH WEEK 100 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS ACROSS ALL SKIN TONES




Andrew Alexis,^{1*} Adrian O Rodriguez,² Geeta Yadav,^{3,4} Mona Shahriari,⁵ Neelam Vashi,⁶ Stephen K Tyring,⁷ Javier Alonso-Llamazares,⁸ Olivia Choi,⁹ Theodore Alkousakis,⁹ Daphne Chan,¹⁰ Tony Ma,¹⁰ Ankita Adhia,¹⁰ Maxwell Sauder,^{3,11} Seemal R Desai^{12,13}

¹Weill Cornell Medicine, New York, NY, USA; ²Nashville Skin Comprehensive Dermatology Center, Nashville, TN, USA; ³University of Toronto, Toronto, ON, Canada; ⁴FACET Dermatology, Toronto, ON, Canada; ⁵Yale University School of Medicine, Central Connecticut Dermatology, Farmington, CT, USA; ⁶Boston University School of Medicine, Boston, MA, USA; ⁷Center for Clinical Studies, Webster, TX, USA; ⁸Driven Research LLC, Coral Gables, FL, USA; ⁹Johnson & Johnson, Horsham, PA, USA; ¹⁰Johnson & Johnson, Spring House, PA, USA; ¹¹Probit Medical Research, Waterloo, ON, Canada; ¹²Innovative Dermatology, Plano, TX, USA; ¹³University of Texas Southwestern Medical Center, Dallas, TX, USA


*Presenting author

OBJECTIVE/METHODS

Evaluate efficacy, safety, and impact of guselkumab (GUS) treatment on patient-reported psoriasis (PsO) symptoms and Health Related Quality of Life (HRQoL) in Cohort A through 2 years



Cohort A Baseline Disease Characteristics*		PBO (N=26)	GUS (N=77)
PsO Duration, y		14.9 (8.8)	14.9 (11.0)
IGA, n (%)			
Moderate 3		21 (80.8)	57 (74.0)
Severe 4		5 (19.2)	20 (26.0)
PSSI (0-72)		19.8 (6.2)	21.2 (9.9)
BSA, %		26.1 (15.9)	27.0 (20.4)



*Mean (SD) unless otherwise noted. BSA=Body surface area; FST= Fitzpatrick skin type; GUS=guselkumab; HRQoL=Health related quality of life; IGA=Investigator's Global Assessment; PSSI=Psoriasis Area and Severity Index; PBO=Placebo; PsO=Psoriasis; PSSI=Psoriasis Scalp Severity Index; q8w=Every 8 weeks; R=Randomized; SD=Standard deviation; SSA=Scalp surface area; ss-IGA=Scalp-specific Investigator's Global Assessment; W=Week.

CONCLUSIONS


Through Year 2, VISIBLE Cohort A study results showed:

- ~70% of all GUS-treated participants achieved clear/almost clear skin (IGA 0/1 and PASI 90)
- >90% mean percent improvement from baseline in BSA and PASI among all GUS-treated participants
- >50% of all GUS-treated participants achieved complete clearance (IGA 0 and PASI 100)
- GUS-treated participants reported significant, clinically meaningful improvements in PsO and PsA symptoms and HRQoL
- No new safety signals were identified
- Clinical responses achieved at Week 16 were generally maintained or improved with continuous GUS treatment, demonstrating high efficacy and durable responses in diverse participants across all objectively measured skin phototypes


RESULTS

- Significantly greater Investigator's Global Assessment (IGA) 0/1, IGA 0, Psoriasis Area and Severity Index (PASI) 90, and PASI 100 response rates were achieved in the GUS-randomized vs PBO group at Week 16. Response rates were generally sustained or improved through Week 100 for both the GUS and placebo (PBO)→GUS groups (non-responder imputation [NRI])
- Mean percent improvements in Body surface area (BSA) and PASI increased over time and were maintained at >90% with continued GUS treatment through Week 100


Proportions of participants achieving IGA 0/1 and PASI 90




Mean percent improvement from baseline in BSA through Week 100



Proportions of participants achieving IGA 0 and PASI 100




Mean percent improvement from baseline in PASI through Week 100




*p<0.05 vs PBO, **p<0.001 vs PBO, p-values were based on the Cochran-Mantel-Haenszel test stratified by FST (I-III/IV-V). *For participants who were randomized to PBO at Week 0, only those who crossed over to GUS at or after Week 16 were included in Weeks 20-100. *Includes participants randomized to GUS at baseline and participants randomized to PBO at baseline who then crossed over to receive GUS at or after Week 16. Participants who discontinued study agent due to lack of efficacy, worsening of PsO, or use of a prohibited PsO treatment prior to designated visit were considered non-responders from that point forward. Participants with missing data were considered non-responders at that time point. CMH=Cochran-Mantel-Haenszel; FST=Fitzpatrick Skin Type; GUS=guselkumab; IGA=Investigator's Global Assessment; PSSI=Psoriasis Area and Severity Index; PBO=placebo; PsO=psoriasis.

- GUS treatment provided significantly greater improvements in patient-reported outcomes (PSSD itch, PsAID-12, SDIEQ, and DLQI) vs PBO at Week 16. Improvements were sustained/improved for the GUS-randomized and PBO→GUS groups through Week 100.


Mean PSSD Itch symptom score through Week 100




Proportion of participants with baseline DLQI >1 achieving a DLQI score of 0/1 through Week 100* (NRI)



Mean PsAID-12 scores through Week 100



Mean SDIEQ scores through Week 100



*nominal p<0.001 vs PBO; p-values for Mean PSSD Itch Symptom Score based on mixed model for repeated measures; explanatory variables included treatment group, visit, baseline score, FST (I-III/IV-V), interaction term of visit with treatment group, and interaction term of visit with baseline score. P-value for Mean SDIEQ Scores based on ANCOVA model. The explanatory variables of the ANCOVA model included treatment group, baseline score, and Fitzpatrick Type (Type I-III/Type IV-V). *For participants who were randomized to PBO at W0, only those who crossed over to GUS at or after W16 were included. Zero change from baseline was assigned if participants discontinued due to lack of efficacy or worsening PsO or used a prohibited PsO treatment (intercurrent events). ΔBL=Mean change from baseline; P-value for proportion of subjects with DLQI=0/1 based on the CMH test stratified by FST (Type I-III/Type IV-V). ANCOVA=Analysis of Covariance; BL=baseline; CMI=Clinically meaningful improvement; DLQI=Dermatology Life Quality Index; FST=Fitzpatrick skin type; GUS=guselkumab; HRQoL=Health Related Quality of Life; NRI=non-responder imputation; PsAID-12=Psoriasis Arthritis Impact of Disease-12 Questionnaire; PBO=placebo; PsO=psoriasis; PSSD=Psoriasis Symptoms and Signs Diary; SDIEQ=Skin Discoloration Impact Evaluation Questionnaire; W=weeks; QoL=quality of life.

GUS-Treated Participant Who Achieved IGA 0 and PASI 100 (Complete Skin Clearance) at Week 16



BSA=Body surface area; GUS=guselkumab; IGA=Investigator's Global Assessment; PASI=Psoriasis Area and Severity Index.

- Following GUS treatment, no new safety signals were observed through Week 112

Key Safety Information	PBO (W0-16) N=26	GUS (W0-16) N=77	PBO→GUS* (W16-112) N=25	GUS (W0-112) N=77
Mean weeks of follow-up	16.0	16.1	91.5	104.4
Participants with ≥1 AE	5 (19.2)	29 (37.7)	13 (52.0)	58 (75.3)
AEs leading to discontinuation of study agent ^b	0	1 (1.3)	0	2 (2.6)
Serious AEs ^c	0	0	1 (4.0)	3 (3.9)
AEs of interest				
Infections	3 (11.5)	16 (20.8)	7 (28.0)	38 (49.4) ^d
Serious infections	0	0	1 (4.0)	3 (3.9)
Clinically important hepatic disorders ^e	0	0	0	0
Major adverse cardiovascular events	0	0	0	0
Malignancy	0	0	0	0
Venous thromboembolism	0	0	0	0
Serum-like sickness or anaphylaxis	0	0	0	0
Tuberculosis	0	0	0	0
Inflammatory bowel disease	0	0	0	0

*For participants randomized to PBO at Week 0, only those who crossed over to GUS at or after Week 16 were included. ^bWeeks 0-16: 1 GUS participant discontinued due to impetiginized atopic dermatitis; Weeks 0-112: Includes 1 GUS participant who discontinued due to pregnancy and the 1 GUS participant with impetiginized atopic dermatitis who discontinued at Weeks 0-16. ^cWeeks 16-112: 1 PBO→GUS participant had localized hand/wrist cellulitis; Weeks 0-112: 1 GUS participant had a gallbladder abscess and bile duct perforation, 1 had appendicitis, and 1 had pyelonephritis. ^dInfections reported in >1 GUS-randomized participant included upper respiratory tract infections (16.9%), nasopharyngitis (11.7%), COVID-19 (6.5%), herpes simplex (2.6%), pharyngitis (2.6%), urinary tract infection (2.6%), and viral upper respiratory tract infection (2.6%). ^eNo clinically important hepatic disorder events based on a narrow Hepatic Disorders Standardised MedDRA Queries search and recorded as serious or leading to treatment discontinuation. AE=adverse event; GUS=guselkumab; MedDRA=Medical Dictionary for Regulatory Activities; PBO=placebo; W=weeks.